The year 2022 has just began. We have entered it with optimism and hope. Whatever the year brings, we will be ready to empower the life sciences industry and regulators to innovate, improve business processes and optimize regulatory information management in the broadest sense for better patient outcomes. We will work hard, forge new partnerships and share our expertise and innovation for the benefit of everyone in the time of the pandemic. We are absolutely driven to increase our efforts and impact with new projects.


2021 was a year of change and hope for a brighter future. Iperion was proud to support life sciences companies and regulators with the ongoing challenges of the global pandemic. Our continued focus on data standardization innovation will, in the end, result in getting vaccines and medicines to patients more quickly than ever before.

We are grateful for all the work we have done and continue to do for our clients and partners. Thanks to all that have contributed to our success. Yes, we are busy. But if you have a regulatory information management challenge and you need our support, please reach out and we will discuss the possibilities. We are here for you!


4 major milestones for Iperion – a Deloitte business of 2021

  1. Early in the year, the European Medicines Agency (EMA) published the EU ISO IDMP Implementation Guides V2.0 and V2.1, that set the clock ticking for life sciences companies doing business in the EU to start getting their data in order and processes in place. Remco Munnik, Associate Director at Iperion, had been working with the group creating the EU IDMP Implementation Guide. He shared his expertise across a number of industry publications as well as hosting a very popular webinar introducing the new process and data requirements.
  2. In May 2021, Iperion Life Sciences Consultancy became a Deloitte business. By combining our specialist industry knowledge and passion with Deloitte’s network and expertise, we hope to make a greater contribution to promoting data standards for better patient outcomes. Joining forces with Deloitte has opened an exciting new chapter full of possibilities.
  3. July brought further progress on IDMP data standards, with tweaks to the Implementation Guide (EU IG 2.1), including provision for use of structured data to report on medicines shortages at a European level for the duration of crisis situations such as the pandemic. Once again we were able to share the inside track on this with our partners and colleagues in the pharmaceutical sector.
  4. In December, we finished the year on a high, welcoming Amy Williams as Director Life Sciences & Healthcare. We know Amy’s deep experience and belief in the importance of integrating RIMS into the primary process of Regulatory Affairs will be a great contribution to our clients’ journey towards digital transformation.